Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.45 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | CD44 | P16070 | 2/20 | 0.43 |
| ▸ | PNMT | P11086 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ASIC3 | Q9UHC3 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30833274 | 0.81 | CD274 (0.46) | CD274PRCPCD44PNMTMAOB | |
| SCHEMBL18554747 | 0.81 | CD274 (0.46) | CD274PRCPCD44PNMTMAOB | |
| SCHEMBL18554680 | 0.81 | ASIC3 (0.46) | PRCPCD44PNMTMAOBCYP3A4 | |
| Hydrochloric Acid SCHEMBL18554740 | 0.80 | CD274 (0.45) | CD274PRCPCD44PNMTMAOB | |
| SCHEMBL20439975 | 0.75 | HTR2C (0.44) | CD44PNMTMAOBASIC3HTR2C | |
| SCHEMBL25244698 | 0.73 | PNMT (0.41) | CD44PNMTMAOBASIC3HTR2C | |
| SCHEMBL6347388 | 0.73 | ASIC3 (0.65) | CD274PRCPCD44PNMTMAOB | |
| SCHEMBL31020006 | 0.73 | PNMT (0.41) | CD44PNMTMAOBASIC3HTR2C | |
| SCHEMBL20425892 | 0.73 | PNMT (0.50) | CD44PNMTMAOBASIC3HTR2C | |
| SCHEMBL4663734 | 0.73 | PNMT (0.59) | CD44PNMTMAOBASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945782-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2024-04-02 | — | — | US | claimed |
| US-10865185-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2020-12-15 | — | — | US | claimed |
| WO-2017035114-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | claimed |
| US-11945782-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2024-04-02 | — | — | US | disclosed |
| US-20210309613-A1 | COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2021-10-07 | — | — | US | disclosed |
| US-20210309613-A1 | COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2021-10-07 | — | — | US | disclosed |
| US-10865185-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865185-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200207718-A1 | COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2020-07-02 | — | — | US | disclosed |
| US-20200207718-A1 | COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2020-07-02 | — | — | US | disclosed |
| EP-3337564-A1 | COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY | Portola Pharmaceuticals, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017034990-A1 | COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2017034990-A1 | COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309613-A1 | COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY | LDLR, PCSK9, CETP | CD274 983/4885PRCP 350/4885CD44 4521/4885 |
| US-10865185-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | LDLR, PCSK9, CETP | CD274 884/4885PRCP 398/4885CD44 4462/4885 |
| US-20200207718-A1 | COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY | LDLR, PCSK9, CETP | CD274 884/4885PRCP 398/4885CD44 4462/4885 |
| US-11945782-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | LDLR, PCSK9, CETP | CD274 983/4885PRCP 350/4885CD44 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.